Evidence map›Paper›PMID 32830303›Full record

ArticlePharmaceutical research2020

Anti-Melanoma Activity of Indomethacin Incorporated into Mesoporous Silica Nanoparticles.

Natália Helen Ferreira, Arthur Barcelos Ribeiro, Francisco Rinaldi-Neto, Fernanda Santos Fernandes, Samuel do Nascimento, Wilson Rodrigues Braz, Eduardo José Nassar, Denise Crispim Tavares

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Research in pharmaceutical sciences · 2024
    Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Natália Helen FerreiraUniversidade de Franca, Avenida Dr. Armando Salles Oliveira, 201 - Parque Universitário, Franca, São Paulo, 14404-600, Brazil. nat_helem@hotmail.com.ORCID http://orcid.org/0000-0002-0052-6139
Arthur Barcelos RibeiroUniversidade de Franca, Avenida Dr. Armando Salles Oliveira, 201 - Parque Universitário, Franca, São Paulo, 14404-600, Brazil.
Francisco Rinaldi-NetoUniversidade de Franca, Avenida Dr. Armando Salles Oliveira, 201 - Parque Universitário, Franca, São Paulo, 14404-600, Brazil.
Fernanda Santos FernandesUniversidade de Franca, Avenida Dr. Armando Salles Oliveira, 201 - Parque Universitário, Franca, São Paulo, 14404-600, Brazil.
Samuel do NascimentoUniversidade de Franca, Avenida Dr. Armando Salles Oliveira, 201 - Parque Universitário, Franca, São Paulo, 14404-600, Brazil.
Wilson Rodrigues BrazUniversidade de Franca, Avenida Dr. Armando Salles Oliveira, 201 - Parque Universitário, Franca, São Paulo, 14404-600, Brazil.
Eduardo José NassarUniversidade de Franca, Avenida Dr. Armando Salles Oliveira, 201 - Parque Universitário, Franca, São Paulo, 14404-600, Brazil.
Denise Crispim TavaresUniversidade de Franca, Avenida Dr. Armando Salles Oliveira, 201 - Parque Universitário, Franca, São Paulo, 14404-600, Brazil.
Universidade de Franca · BR

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 001Fundação de Amparo à Pesquisa do Estado de São Paulo 2016/24269-7
6 · The paper itself

Abstract

Melanoma is the deadliest type of skin cancer. Treatments that directly address tumor survival are required. Indomethacin (IND) is a well-known drug used worldwide. Although widely used as a therapeutic agent, IND has undesirable gastrointestinal effects. PURPOSE: To investigate the antitumor efficacy of IND incorporated into mesoporous silica nanoparticles (MSNPs+IND), as well as its toxic potential in a syngeneic murine B16 melanoma model.

methodsAntitumor activity was evaluated by measuring tumor size and weight and by histopathological analysis. Possible molecular signaling pathways involved in the antitumor activity were analyzed by Western blot in liver tissue and by immunohistochemistry in tumor tissue. The potential toxicity was evaluated by determining body and organ weights and by biochemical and genotoxic analysis.

resultsMSNPs+IND treatments inhibited tumor growth by up to 70.09% and decreased the frequency of mitosis in tumor tissues, which was up to 37.95% lower compared to the IND groups. In hepatic tissue, COX-2 levels decreased significantly after treatment with MSNPs+IND and IND. Additionally, MSNPs+IND and IND increased the levels of cleaved caspase-3 (156.25% and 137.50%, respectively), inducing tumor cell apoptosis. Genotoxicity was limited to the group treated with the higher concentration of IND, while MSNPs prevented IND-induced genotoxicity.

conclusionsMSNPs may be promising for future applications in cancer therapy.

Indexed as

AnimalsAntineoplastic AgentsCaspase 3Cell Line, TumorCyclooxygenase 2Drug CarriersDrug Delivery SystemsIndomethacinMaleMelanomaMiceMice, Inbred C57BLMitosisNanoparticlesPorositySilicon DioxideAntineoplastic AgentsCasp3 protein, mouseCaspase 3Cyclooxygenase 2Drug CarriersIndomethacinPtgs2 protein, mouseSilicon Dioxideapoptosiscleaved caspase-3COX-2 inhibitioninhibition of tumor growth

Identifiers

PMID32830303
OpenAlexW3081000245

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.